Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib vs Bempedoic Acid in Dyslipidemia
NCT07614958Phase 3Recruiting
- Sponsor
- Menarini Group
- Start
- May 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 3 trial of obicetrapib in dyslipidemia, hypercholesterolemia, sponsored by Menarini Group. Started May 2026; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT07614958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614958.